News Center

Home page

Peak Report

News reports

Jianfeng Group Pro 2015-007 (Jianfeng Group Daily Related Party Transaction Announcement)

Release time:

2020-08-05

Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-007

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Regular Related Party Transaction Announcement

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .

Basic Information of 1. Daily Related Party Transactions

Review Procedures for Implementation of (I) Daily Related Party Transactions

Jinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinhua Pharmaceutical Company") purchases drugs from related party Tianjin Tianshili Pharmaceutical Marketing Group Co., Ltd. (hereinafter referred to as "Tianshili Marketing Group"). It is estimated that the purchase amount in 2015 will be between 0.5 and 5% of the company's audited net assets at the end of 2014 (no more than 103.0351 million yuan). Therefore, this related party transaction needs to be submitted to the board of directors for deliberation, but does not need to be submitted to the general meeting of shareholders for deliberation.

On April 17, 2015, the company held the second meeting of the ninth board of directors. All nine directors of the company attended the meeting in person. The related directors Mr. Jiang Xiaomeng and Mr. Du Zihong avoided voting on the proposal, which complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and effective. After deliberation and voting, the board of directors deliberated and passed the daily related party transaction proposal with 7 votes in favor, 0 votes against and 0 abstention.

The independent directors of the company reviewed the matter in advance and agreed to submit the proposal to the second meeting of the ninth board of directors of the company for deliberation. The independent directors of the company expressed their independent opinions on the adoption of the proposal by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the company's "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.

Forecast and Implementation of (II)'s Last Daily Related Party Transaction

The Company issued a public announcement on April 15, 2014. It is estimated that the amount of drugs purchased by Jinhua Pharmaceutical Company from Tianshili Marketing Group in 2014 will be between 0.5 and 5% (between 8.685 million yuan and 86.8499 million yuan) of the Company's audited net assets at the end of 2013. The actual amount incurred in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions, which did not exceed the expected range.

2. Related Party Introduction and Association Relationship

(I) the basic situation of related parties.

1. Jinhua Pharmaceutical Company: Established in January 1994, its domicile is located at 1180 Huancheng East Road, Jinhua City, its legal representative is Jin Xuecai, and its registered capital is 22 million yuan, of which: the company accounts for 10%, Zhejiang Jianfeng Pharmaceutical Co., Ltd., its holding subsidiary, accounts for 90%, and its main business is drug management. Wholesale and retail of prepackaged food; dangerous chemicals and medical devices; chemical reagents (except dangerous goods); glass and products; textiles, clothing and household daily necessities (except dangerous goods); fitness equipment supplies; computers, software and auxiliary equipment; wholesale and retail of teaching molds; exhibition services; medical information services; branches operate with valid certificates: purchase and processing of traditional Chinese medicine. The drug business license mainly includes: sales of proprietary Chinese medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. The audited net profit for 2014 was 6.5056 million yuan, the net assets at the end of 2014 was 73.169 million yuan, and the liabilities were 237.9614 million yuan.

2, Tianshili Marketing Group: The company was established in 1999 February. The company's domicile is Tianshili Modern Chinese Medicine City, Xinyibai Avenue, Beichen Science and Technology Park, Tianjin, with its legal representative Yan Kaijing and registered capital of 25900 yuan, the business scope is the wholesale of Chinese herbal pieces, Chinese medicinal materials, Chinese patent medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, biological products, and diagnostic drugs; chemical raw materials ( except hazardous chemicals and precursor drugs ) , Wholesale and retail of cosmetics, daily chemical products, packaging materials and containers, plastic products, molds, and plastic raw materials; health food (hard capsules, soft capsules, granules, tablets, oral liquids, tea bags, health wine) wholesale and retail; disposable sterile syringes (needles), infusion sets (needles), corneal contact lenses and nursing solutions, medical polymer materials and products, physical therapy and rehabilitation equipment, medical hygiene materials and dressings, Chinese medicine equipment, general diagnosis equipment, Ward care equipment and appliances, household blood glucose meters and test strips, pregnancy diagnosis test strips, condoms wholesale; self-employed and agent of all kinds of goods and technology import and export business, but the state restricts the company to operate or prohibits the import and export of goods and technology, operating feed processing and "three to one supplement " business, operating trade and re-export trade, pre-packaged food wholesale and retail. The net profit attributable to the parent company in 2014 was 16,080.14 yuan, The net assets attributable to the parent company at the end of 2014 were 9,234.05 yuan, and the liabilities were 482,239.84 yuan.

The relationship between the (II) and the listed company

Because Tianshili Marketing Group is the holding subsidiary of Tianshili Pharmaceutical Group Co., Ltd., and Tianshili Pharmaceutical Group Co., Ltd. is the holding subsidiary of Tianshili Holding Group Co., Ltd. (hereinafter referred to as "Tianshili Group"), tasly Group is an associate of the Company and the Company has two directors who are also directors of Tasly Group, so Jinhua Pharmaceutical Company is related to Tasly Marketing Group.

(III) The amount of related party transactions in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions. The implementation was good and there were no disputes.

Main Contents and Pricing Policy of 3. Related Party Transaction

Jinhua Pharmaceutical Company plans to continue to purchase drugs from Tianshili Marketing Group for sale this year. The main contents of this related party transaction are as follows:

(1) Transaction Target: Compound Danshen Dripping Pills, Yangxue Qingnao Granules, etc.

(2) Transaction Price: Agreement Price.

(3) settlement method: full payment according to the sales amount of last month.

(4) Agreement Validity Period: The validity period of the agreement signed by the above-mentioned related parties is 1 year from the date of signature by the legal representatives or authorized representatives of both parties.

(5) Other matters: If there is a major change in the content of this related party transaction during the implementation of the agreement, the company will disclose it in accordance with relevant regulations, and investors are requested to pay attention.

Purpose of 4. Related Party Transaction and Impact on Listed Companies

This related party transaction is to use Jinhua Pharmaceutical Company's existing sales network in Zhejiang Province to purchase drugs from Tianshili Marketing Group for distribution and sales, thus expanding Jinhua Pharmaceutical Company's business scope, further enhancing the Company's market influence and enhancing the Company's marketing capability. At the same time, Tasly Marketing Group is an indirect holding subsidiary of the Company's associates, and the expansion of its sales channels has increased the scale of corporate sales. The connected transaction will not harm the interests of the Company or the minority shareholders.

hereby announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

April 21, 2015

More information

City Red Cross thanks spike help "anti-epidemic"

On February 26, Jinhua City Red Cross Party Secretary, Executive Vice President Shi Yiwei and his entourage to visit the peak, the peak in the prevention and control of the new coronary pneumonia epidemic actively contribute to love, brave social responsibility of the great love and kindness to express gratitude. Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and Xiang Chongping, deputy general manager of the group company, had a discussion with Vice President Shi Yiwei and his party. In order to solve the difficult problems for caring enterprises to resume work and production, the Municipal Red Cross Society, based on its own functional positioning and giving full play to its unique advantages, conducted a large feedback and return visit to caring enterprises, and jointly established three Red Cross volunteer service teams, including traditional Chinese medicine service, psychological assistance, and emergency rescue training, to take "eight measures" to help caring enterprises resume work and production. Vice President Shi Yiwei led the backbone of three volunteer service teams to the peak for a return visit, expressing his gratitude for the contribution made by the peak in the prevention and control of the new coronary pneumonia epidemic, and sent a letter of thanks and the "New Coronary Pneumonia Prevention and Control Enterprises Resuming Work and Resuming Production Protection Manual". Chairman Jiang Xiaomeng introduced the industrial layout, production and operation of the peak, focusing on the resumption of work and production of the peak enterprises, and put forward opinions and suggestions on the reduction and exemption of basic electricity charges for enterprises, the support policies for small and medium-sized enterprises, and the payment of "five insurance and one fund. (Reporter Ni Yingzhen)

2020

07-15

Peak 2013 corporate bonds complete principal and interest payments

News from our newspaper On November 20, Zhejiang Jianfeng Group Co., Ltd. successfully completed the payment of principal and interest on 2013 corporate bonds (Phase II) (hereinafter referred to as "13 Jianfeng 02"). At this point, all the corporate bonds approved for issuance in 2013 have been paid. In 2013, with the approval of document No. [2013]595 of China Securities Regulatory Commission, the company was allowed to issue corporate bonds with a face value of no more than 0.6 billion yuan to the public, with a debt rating of AA +. On June 5, 2013, the Company issued the 2013 Corporate Bonds (Phase I) ("13 Peak 01"), which raised $0.3 billion at a coupon rate of 4.90 per cent, 1.55 percentage points lower than the then five-year benchmark interest rate for bank loans. On November 20, 2014, "13 Peak 02" was successfully issued, raising 0.3 billion yuan again at a coupon rate of 5.09, and was listed on the Shanghai Stock Exchange on December 11, 2014. The ability to raise 0.6 billion yuan from the capital market at a lower cost reflects investors' recognition of the company's "cement + pharmaceutical" dual business structure and expectations of the company's good operating performance. On June 5, 2018, the first issue of Jianfeng Group's 2013 corporate bonds was due to complete the payment of principal and interest, and now the second issue of corporate bonds has also successfully completed the payment of principal and interest. In the real economic growth is weak, business operations continue to explode, the company in a short period of time successfully completed two issues of a total of 0.6 billion yuan of corporate bonds principal and interest payment work, fully reflecting the company's good operating results in recent years.

2020

07-31

Company Leaders Attend Jinhua Development Conference

News from our newspaper On November 17, the second 2019 Jinhua Development Conference with the theme of "Insist on high-quality integration into the Yangtze River Delta to build a metropolitan area" opened in Jinhua, Zhejiang. More than a thousand people from the scientific and educational circles, business circles, and overseas Chinese from home and abroad Business people, representatives of "New Golden Chinese" and representatives of outstanding Jinhua students attended the meeting. Group leaders Jiang Xiaomeng, Yu Jianhong and Huang Jinlong attended the relevant activities of the conference. As a representative of the Jinhua business community, Jiang Xiaomeng, chairman of the group company, made a keynote speech at the "Scientist" and "Entrepreneur" Innovation Dialogue of the Development Conference, expressing his views on how Jinhua enterprises can improve their technological competitiveness. As the head of Jinhua local enterprise with a history of more than 60 years, Jiang Xiaomeng has a profound experience in promoting the development of enterprises through science and technology. Combined with the reality of peak scientific and technological innovation, he pointed out in his speech that the improvement of scientific and technological innovation ability is an urgent event for Jinhua small and medium-sized enterprises. Private enterprises cannot achieve high-quality development without the support of scientific and technological forces; with the progress of society, the improvement of people's living standards and the continuous improvement of cultural quality, the demand for products and the pursuit of product quality have also undergone qualitative changes. Only products with scientific and technological connotations can attract consumers. He suggested that the government and relevant institutions should establish an information platform to further understand the scientific and technological support that enterprises need in the transformation, understand what kind of help scientific and technological personnel can provide to enterprises, do a good job in the information docking of scientists and entrepreneurs, further attract investment and wisdom, give full play to the scientific and technological achievements of academicians and experts and the capital advantages of businessmen at home and abroad, and promote Jinhua enterprises to better integrate into Changsan

2020

07-31

Company Leaders Attend Jinhua Development Conference

2020

07-22

The Party Committee of the Group conducts thematic education and concentrated study.

On November 12, the Party Committee of the Group Company held a "Do not forget your initiative mind, Keeping in mind the mission" thematic education and study meeting to focus on the relevant spirit of the central and higher Party committees on thematic education and the key points in the "Decision of the Central Committee of the Communist Party of China on Adhering to and Improving the Socialist System with Chinese Characteristics, Promoting the Modernization of the National Governance System and Governance Capacity" previously held at the Fourth Plenary Session of the 19th CPC Central Committee of the 19th CPC Central Committee, and make arrangements for further promoting thematic education in the whole group. According to the central government's schedule for the second batch of thematic education, the group party committee requires all party members and cadres to deeply understand the significance of carrying out the thematic education of "not forgetting the original heart and keeping in mind the mission", and firmly grasp the "keep the original heart, undertake the mission, find the gap, and grasp the implementation" The general requirements of the group party committee members will also go to various enterprises separately in the near future, carry out research on the development of theme education, the current difficulties faced by enterprises and the issues of concern to employees, so as to achieve the effect of closely combining theme education with the promotion of enterprise management, and strengthening the close combination of party building and enterprise development. (this newspaper reporter)

2020

07-31

Company Leaders Attend Jinhua Development Conference

2020

07-31

< 1...26 27 28...61 > 跳转到页